middle.news
Bubs clears FDA hurdle as US growth drives FY26 earnings recovery
8:42am on Wednesday 14th of October, 2026 AEDT
•
Consumer Staples
Read Story
Bubs clears FDA hurdle as US growth drives FY26 earnings recovery
8:42am on Wednesday 14th of October, 2026 AEDT
Key Points
Revenue up 9.2% to $111.9 million
Underlying EBITDA rises to $5.3 million from $1.2 million
Statutory loss of $4.6 million after $15.1 million operating cash outflow
US revenue grows 24% to $65.8 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Bubs Australia (ASX:BUB)
OPEN ARTICLE